FibroGen, Inc. (NASDAQ:FGEN) Shares Acquired by Fmr LLC

Fmr LLC grew its holdings in shares of FibroGen, Inc. (NASDAQ:FGEN) by 21.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 383,258 shares of the biopharmaceutical company’s stock after purchasing an additional 68,569 shares during the quarter. Fmr LLC’s holdings in FibroGen were worth $153,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. Acadian Asset Management LLC grew its position in FibroGen by 34.4% in the second quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock worth $2,997,000 after acquiring an additional 860,854 shares during the period. Doheny Asset Management CA purchased a new position in FibroGen in the 2nd quarter valued at approximately $48,000. XTX Topco Ltd purchased a new stake in FibroGen during the 2nd quarter worth about $424,000. Sei Investments Co. grew its holdings in FibroGen by 38.4% during the 2nd quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 41,442 shares in the last quarter. Finally, Point72 DIFC Ltd raised its stake in FibroGen by 734.2% in the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 45,990 shares in the last quarter. 72.71% of the stock is owned by hedge funds and other institutional investors.

FibroGen Stock Performance

Shares of FGEN opened at $0.40 on Monday. The stock has a fifty day moving average of $0.35 and a two-hundred day moving average of $0.56. FibroGen, Inc. has a fifty-two week low of $0.18 and a fifty-two week high of $2.93. The company has a market capitalization of $40.31 million, a PE ratio of -0.33 and a beta of 0.82.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.21. The firm had revenue of $46.33 million for the quarter, compared to analyst estimates of $34.00 million. During the same quarter in the prior year, the company earned ($0.52) earnings per share. As a group, equities research analysts forecast that FibroGen, Inc. will post -0.86 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

FGEN has been the topic of several research analyst reports. StockNews.com began coverage on shares of FibroGen in a research note on Monday, December 16th. They set a “hold” rating on the stock. HC Wainwright raised shares of FibroGen to a “strong-buy” rating in a research note on Tuesday, December 17th. Finally, William Blair reiterated a “market perform” rating on shares of FibroGen in a research report on Wednesday, November 13th.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.